KALAMAZOO, Mich., April 20 /PRNewswire-FirstCall/ -- Stryker Corporation
(NYSE: SYK) reported operating results for the quarter ended March 31, 2009 as
follows:
First Quarter Highlights
-- Net sales increased 3.3% on a constant currency basis (2.0% decrease
as reported) to $1,601 million
-- Orthopaedic Implants sales increased 6.2% on a constant currency basis
(0.2% increase as reported)
-- MedSurg Equipment sales decreased 1.0% on a constant currency basis
(5.3% decrease as reported)
-- Net earnings decreased 3.2% from $291 million to $281 million
-- Diluted net earnings per share increased 1.4% from $0.70 to $0.71
"The unprecedented global economic slowdown clearly impacted our business,
yet our diverse set of businesses still delivered underlying sales growth in
this very challenging period as six of our eight key product franchises
delivered mid-single to low double-digit constant currency revenue growth,"
commented Stephen P. MacMillan, President and Chief Executive Officer.
Net sales were $1,601 million for the first quarter of 2009, representing
a 2.0% decrease compared to net sales of $1,634 million for the first quarter
of 2008. On a constant currency basis, net sales increased 3.3% for the first
quarter.
Net earnings for the first quarter of 2009 were $281 million, representing
a 3.2% decrease compared to net earnings of $291 million for the first quarter
of 2008. Diluted net earnings per share for the first quarter of 2009
increased 1.4% to $0.71 compared to $0.70 for the first quarter of 2008.
Sales Analysis
Domestic sales were $1,042 million for the first quarter of 2009,
representing an increase of 0.9%, as a result of higher shipments of
Orthopaedic Implants partially offset by lower shipments of MedSurg Equipment.
International sales were $559 million for the first quarter of 2009,
representing a decrease of 7.0%. The impact of foreign currency comparisons
to the dollar value of international sales was unfavorable by $87 million in
the first quarter of 2009. On a constant currency basis, international sales
increased 7.4% in the first quarter of 2009, as a result of higher shipments
of Orthopaedic Implants and MedSurg Equipment.
Worldwide sales of Orthopaedic Implants were $973 million for the first
quarter of 2009, representing an increase of 0.2%. On a constant currency
basis, sales of Orthopaedic Implants increased 6.2% in the first quarter of
2009, based on higher shipments of reconstructive, trauma, spinal and
craniomaxillofacial implant systems.
Worldwide sales of MedSurg Equipment were $628 million for the first
quarter of 2009, representing a decrease of 5.3%. On a constant currency
basis, sales of MedSurg Equipment decreased 1.0% in the first quarter of 2009,
as higher shipments of surgical equipment and surgical navigation systems were
offset by lower sales of endoscopic, communications and digital imaging
systems and patient handling and emergency medical equipment.
Income Taxes
The Company's effective income tax rate for the first quarter of 2009 was
27.3%, as compared to effective income tax rates for the first quarter of 2008
and year ended December 31, 2008 of 28.1% and 27.4%, respectively.
In April 2009 the U.S. Internal Revenue Service (IRS) issued two notices
of proposed tax adjustments to the Company's previously filed 2003, 2004 and
2005 income tax returns related to income tax positions the Company has taken
for its cost sharing arrangements with two wholly owned entities operating in
Ireland. The Company believes it followed the applicable tax law and Treasury
regulations and will vigorously defend these income tax positions. If the IRS
were ultimately to prevail with respect to its proposed tax adjustments, such
adjustments could have a material unfavorable impact on the Company's income
tax expense and net earnings in future periods.
Outlook for 2009
As a result of the continued weaker demand for certain MedSurg Equipment
products as well as consideration of slowing elective procedures for certain
Orthopaedic Implant products, the Company is reducing its guidance for 2009.
The Company now projects that diluted net earnings per share for 2009 will
be in the range of $2.90 to $3.10, an increase of 2% to 10% over adjusted
diluted net earnings per share of $2.83 in 2008. The financial forecast for
2009 anticipates a constant currency net sales increase in the range of 2% to
5%. If foreign currency exchange rates hold near March 31, 2009 levels, the
Company anticipates an unfavorable impact on net sales of approximately 5.5%
to 6.0% in the second quarter of 2009 and an unfavorable impact on net sales
of approximately 3.5% to 4.5% for the full year of 2009.
Conference Call
As previously announced, the Company will conduct a conference call for
financial analysts at 4:30 p.m., Eastern Time, today. To participate in the
conference call dial 866-700-5192 (domestic) or 617-213-8833 (international)
and enter the participant passcode 24899716. A simultaneous webcast of the
call will be accessible via the Company's website at www.stryker.com. The call
will be archived on this site for 90 days.
A recording of the call will also be available from 7:30 p.m., Eastern
Time, on Monday, April 20, 2009, until 7:30 p.m. on Monday, April 27, 2009. To
hear this recording, dial 888-286-8010 (domestic) or 617-801-6888
(international) and enter the passcode 86263096.
Forward-Looking Statements
Certain statements made during the call may constitute forward-looking
statements. They will be based upon management's current expectations and will
be subject to various risks and uncertainties that could cause the Company's
actual results to differ materially from those expressed or implied in such
statements. Such factors include, but are not limited to: further weakening of
economic conditions that could adversely affect the level of demand for the
Company's products; pricing pressures generally, including cost-containment
measures that could adversely affect the price of or demand for the Company's
products; changes in foreign exchange markets; regulatory actions;
unanticipated issues arising in connection with clinical studies and otherwise
that affect U.S. Food and Drug Administration approval of new products;
changes in reimbursement levels from third-party payors; a significant
increase in product liability claims; unfavorable resolution of income tax
audits; changes in financial markets; and changes in the competitive
environment. Additional information concerning these and other factors is
contained in the Company's filings with the U.S. Securities and Exchange
Commission, including the Company's Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q.
Stryker Corporation is one of the world's leading medical technology
companies with the most broadly based range of products in orthopaedics and a
significant presence in other medical specialties. Stryker works with
respected medical professionals to help people lead more active and more
satisfying lives. The Company's products include implants used in joint
replacement, trauma, craniomaxillofacial and spinal surgeries; biologics;
surgical, neurologic, ear, nose & throat and interventional pain equipment;
endoscopic, surgical navigation, communications and digital imaging systems;
as well as patient handling and emergency medical equipment. For more
information about Stryker, please visit www.stryker.com.
STRYKER CORPORATION
For the Three Month Period Ended March 31, 2009
(Unaudited - In Millions Except Per Share Amounts)
First Quarter
CONDENSED STATEMENTS OF EARNINGS 2009 2008 % Change
Net sales $1,601.3 $1,634.4 (2.0)
Cost of sales 515.5 500.5 3.0
GROSS PROFIT 1,085.8 1,133.9 (4.2)
% of Sales 67.8 69.4
Research, development and
engineering expenses 80.4 85.1 (5.5)
Selling, general and
administrative expenses 616.6 654.5 (5.8)
Intangibles amortization 9.6 10.6 (9.4)
706.6 750.2 (5.8)
OPERATING INCOME 379.2 383.7 (1.2)
% of Sales 23.7 23.5
Other income (expense) 7.2 20.3 (64.5)
EARNINGS BEFORE INCOME TAXES 386.4 404.0 (4.4)
Income taxes 105.3 113.5 (7.2)
NET EARNINGS $281.1 $290.5 (3.2)
Net Earnings Per Share:
Basic $0.71 $0.71 -
Diluted $0.71 $0.70 1.4
Average Shares Outstanding
Basic 396.7 411.4
Diluted 398.6 417.9
STRYKER CORPORATION
For the Three Month Period Ended March 31, 2009
(Unaudited - In Millions)
First Quarter
% Change
Constant
CONDENSED SALES ANALYSIS 2009 2008 Reported Currency
Domestic $1,042.0 $1,032.9 0.9 0.9
International 559.3 601.5 (7.0) 7.4
NET SALES $1,601.3 $1,634.4 (2.0) 3.3
Orthopaedic Implants $973.2 $971.1 0.2 6.2
MedSurg Equipment 628.1 663.3 (5.3) (1.0)
NET SALES $1,601.3 $1,634.4 (2.0) 3.3
First Quarter 2009
% Change
Domestic International Total
SUPPLEMENTAL SALES Constant Constant
GROWTH ANALYSIS Reported Reported Currency Reported Currency
Orthopaedic Implants sales:
Hips 3 (7) 9 (2) 6
Knees 8 (12) 4 1 6
Trauma 10 (3) 6 2 8
Spine 13 (2) 9 8 11
Craniomaxillofacial 12 (14) 0 3 8
Total Orthopaedic
Implants 6 (7) 7 0 6
MedSurg Equipment sales:
Surgical equipment and
surgical navigation
systems 11 (12) 3 4 8
Endoscopic,
communications and
digital imaging
systems (7) (1) 16 (5) (1)
Patient handling and
emergency medical
equipment (27) (1) 18 (22) (18)
Total MedSurg Equipment (5) (7) 10 (5) (1)
STRYKER CORPORATION
(Unaudited - In Millions)
March 31 December 31
CONDENSED BALANCE SHEETS 2009 2008
ASSETS
Cash and cash equivalents $685.8 $701.1
Marketable securities 1,559.3 1,494.5
Accounts receivable (net) 1,054.8 1,129.5
Inventories 990.2 952.7
Other current assets 709.8 701.5
TOTAL CURRENT ASSETS 4,999.9 4,979.3
Property, Plant and Equipment (net) 944.3 963.8
Goodwill and Other Intangibles (net) 909.5 935.5
Other Assets 731.5 724.7
TOTAL ASSETS $7,585.2 $7,603.3
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities $1,181.8 $1,462.1
Other Liabilities 778.3 734.5
Shareholders' Equity 5,625.1 5,406.7
TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY $7,585.2 $7,603.3
STRYKER CORPORATION
For the Three Month Period Ended March 31, 2009
(Unaudited - In Millions)
First Quarter
CONDENSED STATEMENTS OF CASH FLOWS 2009 2008
OPERATING ACTIVITIES
Net earnings from continuing operations $281.1 $290.5
Depreciation 37.9 38.7
Amortization 53.8 59.5
Changes in working capital and other (100.4) (197.9)
NET CASH PROVIDED BY OPERATING ACTIVITIES 272.4 190.8
INVESTING ACTIVITIES
Acquisitions, net of cash acquired (2.6) (6.2)
Proceeds from sales of (purchases of)
marketable securities, net (98.2) 91.6
Purchases of property, plant and equipment (30.6) (30.9)
Proceeds from sales of property, plant and
equipment 0.7 0.1
NET CASH PROVIDED BY (USED IN) INVESTING
ACTIVITIES (130.7) 54.6
FINANCING ACTIVITIES
Proceeds from borrowings, net 0.9 0.8
Dividends paid (158.6) (135.6)
Other 24.0 4.5
NET CASH USED IN FINANCING ACTIVITIES (133.7) (130.3)
Effect of exchange rate changes on cash and
cash equivalents (23.3) 17.9
CHANGE IN CASH AND CASH EQUIVALENTS $(15.3) $133.0
SOURCE Stryker Corporation
CONTACT: Katherine A. Owen,
Vice President, Strategy and Investor
Relations,
+1-269-385-2600/